Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

46 items

Reflex testing on newly diagnosed tumours with uveal melanoma.

Funded Biomarker Disease Site: Ocular

Biomarker: GNAQ, GNA11

Testing Method:Panel

Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Reflex testing should be performed on tumours from newly diagnosed adult patients with astrocytic and oligodendroglial tumours, including glioblastomas (all diffuse high-grade gliomas Stage III and IV).

Funded Biomarker Disease Site: Central Nervous System (CNS)

Biomarker: IDH R132H, P53, ATRX

Testing Method:Immunohistochemistry (IHC)

Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network

Reflex testing to confirm or exclude small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).

Funded Biomarker Disease Site: Ovary

Biomarker: SMARCA4

Testing Method:Panel

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Trillium Health Partners, University Health Network, William Osler Health System

Reflex tumour testing for all patients diagnosed with high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Funded Biomarker Disease Site: Ovary

Biomarker: BRCA1, BRCA2

Testing Method:Panel

Testing on advanced/metastatic breast cancer where directed therapy is being considered.

Funded Biomarker Disease Site: Breast

Biomarker: ESR1, PIK3CA

Testing Method:Panel

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Testing on patients previously diagnosed with locally advanced or metastatic NSCLC who have progressed on or after EGFR TKI therapy.

Funded Biomarker Disease Site: Lung

Biomarker: Acquired EGFR T790M

Testing Method:Sequencing

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Testing on previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) where FGFR2 directed therapy is being considered

Funded Biomarker Disease Site: Hepatobiliary

Biomarker: FGFR2

Testing Method:Sequencing

Testing Site: Hamilton Health Sciences, Hospital for Sick Children (SickKids), London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Testing to support diagnosis of nasopharyngeal carcinoma (newly diagnosed or suspected nasopharyngeal carcinoma).

Funded Biomarker Disease Site: Head and Neck

Biomarker: EBER

Testing Method:In Situ Hybridization (ISH)

Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Testing to support diagnosis of sex-cord stromal tumours.

Funded Biomarker Disease Site: Ovary

Biomarker: DICER1, FOXL2

Testing Method:Panel

Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Trillium Health Partners, University Health Network

Testing to support newly diagnosed adult cases of Ependymoma (spinal cord).

Funded Biomarker Disease Site: Central Nervous System (CNS)

Biomarker: MYCN Amplification

Testing Method:Fluoroscence In Situ Hybridization (FISH), Single Nucleotide Polymorphism (SNP) Array

Testing Site: London Health Sciences Centre, Trillium Health Partners

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Biomarker Testing

Funded Biomarker Testing

Reflex testing on newly diagnosed tumours with uveal melanoma.

Reflex testing should be performed on tumours from newly diagnosed adult patients with astrocytic and oligodendroglial tumours, including glioblastomas (all diffuse high-grade gliomas Stage III and IV).

Reflex testing to confirm or exclude small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).

Reflex tumour testing for all patients diagnosed with high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Testing on advanced/metastatic breast cancer where directed therapy is being considered.

Testing on patients previously diagnosed with locally advanced or metastatic NSCLC who have progressed on or after EGFR TKI therapy.

Testing on previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) where FGFR2 directed therapy is being considered

Testing to support diagnosis of nasopharyngeal carcinoma (newly diagnosed or suspected nasopharyngeal carcinoma).

Testing to support diagnosis of sex-cord stromal tumours.

Testing to support newly diagnosed adult cases of Ependymoma (spinal cord).

Pages